Explore the vast range of titles available.

A locally resonant metastructure is a promising approach for low-frequency vibration attenuation, whereas the attachment of many resonators results in unnecessary and multiple resonance outside the bandgap. To address this issue, we propose a damping metastructure combining local resonators and an autonomous synchronized switch damping circuit. On the basis of modal analysis, we derive an electromechanically coupled equation of the proposed metastructure. The piezo ceramics, which are attached on a small portion of the metastructure and connected to the circuit, remarkably decrease the magnitude of the resonant vibration with no extra sensors, signal processors, or power sources. The displacement at unnecessary resonance was decreased by approximately 75%. The results of the coupled analysis were similar to the experimentally observed results in terms of the location and width of the bandgap on the frequency axis and the decreased displacement for the circuit. The proposed technique can overcome the disadvantage of the metastructure.

In this research, a novel variable stiffness vibration isolator that uses magnetorheological elastomers (MREs) accompanied with a fuzzy semiactive vibration control was developed. Firstly, the viscoelastic characteristics of MREs in shear mode were clarified systematically in order to achieve a mathematical basis for the controller development. Secondly, the fuzzy semiactive vibration control with a strategy based on the Lyapunov theory and dynamic characteristic of MREs was proposed for minimizing the movement of the isolator. In the conventional semiactive algorithm, the command applied current of MRE-based isolator is set at either minimum or maximum value which causes high acceleration and jerk peaks periodically, thus leading to the degeneration of the overall system quality. However, the fuzzy semiactive algorithm presented here is able to produce the sufficient applied current and thus viscoelastic force is desirably produced. The effectiveness of the developed isolator was evaluated numerically by MATLAB simulation and experimentally in comparison with the performances of a passive system and a system with on-off type semiactive controller. The results showed that the developed controller was successful in overcoming the disadvantages of conventional on-off semiactive control.

To downsize the clamp area and increase the output power of the harvester, we developed a miniature piezoelectric vibration energy harvester with combining a Z-shaped folded spring and a mechanically-switching SSHI (synchronized switch harvesting on inductor). The overall harvester size is 4×2×3 cm3. The FEM analysis revealed that the output power increases and the value of the 1st and 2nd resonance frequencies move closer as the angle of the Z-shaped spring decreases, therefore, the smaller angle would be more promising. The experimental results showed that the maximum output power of our harvester for the 1st (20.2 Hz) and 2nd (53.0 Hz) resonance frequencies at the applied acceleration of 4.9 m/s2 are 088 and 0.98 mW, respectively. The reason for a marked enhancement of the output power for the 2nd resonance frequency is attributed to the vertical movement of the 2nd vibrational mode which applies larger mechanical stress to the piezo ceramic and achieves better electrical contact between the tip of the Z-shaped spring and the spring plunger.

We propose a fine-grained stainless-steel as a promising material for a robust oscillator and investigate the dependence of frequency band width, resonance frequency, and output power on initial air gaps in electret-based vertical vibration energy harvesters. Beams of the oscillator showed a shallow side-etched depth less than 10 μm, as well as smooth edges. The oscillator succeeded in travelling over 1-mm displacement without fracture. Also, we found that broader frequency band, as well as lower resonance frequency, can be achieved with reducing the initial air gap, whereas the output power exhibited a peak value at an optimal initial air gap. The results may be attributed to the soft spring effect induced by the stronger electrostatic force. Maximum output power density and FWHM of frequency band width of our harvester are 4.7 μW/cm3 and 14 Hz at initial air gap 0.3 mm and acceleration 4.9 m/s2.

Aiming at longer stability of surface potential, we propose a ferroelectric dipole electret (FDE) prepared from hard ferroelectric material. We compared output power of electrostatic vibration energy harvester and surface potential stability between FDEs prepared from soft and hard PZT ceramics, as well as a CYTOP polymer electret. The hard FDE showed a seven-fold increase in output power over the soft FDE and nine-fold increase over the CYTOP polymer electret. The hard FDE also showed longer stability of surface potential than that of the soft FDE, whereas the stability of the hard FDE was not yet comparable to that of CYTOP polymer electret. A FDE prepared from harder PZT ceramic (with higher coercive electric field and Curie temperature) may provide more stability in surface potential.

Background Soft tissue sarcomas (STS) are a rare type of malignancy comprising a variety of histological diagnoses. Chemotherapy constitutes the standard treatment for advanced STS. Doxorubicin-based regimens, which include the administration of doxorubicin alone or in combination with ifosfamide or dacarbazine, are widely accepted as first-line chemotherapy for advanced STS. Trabectedin, eribulin, pazopanib, and gemcitabine plus docetaxel (GD), which is the empirical standard therapy in Japan, are major candidates for second-line chemotherapy for advanced STS, although clear evidence of the superiority of any one regimen is lacking. The Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group (JCOG) conducts this trial to select the most promising regimen among trabectedin, eribulin, and pazopanib for comparison with GD as the test arm regimen in a future phase III trial of second-line treatment for patients with advanced STS. Methods The JCOG1802 study is a multicenter, selection design, randomized phase II trial comparing trabectedin (1.2 mg/m 2 intravenously, every 3 weeks), eribulin (1.4 mg/m 2 intravenously, days 1 and 8, every 3 weeks), and pazopanib (800 mg orally, every day) in patients with unresectable or metastatic STS refractory to doxorubicin-based first-line chemotherapy. The principal eligibility criteria are patients aged 16 years or above; unresectable and/or metastatic STS; exacerbation within 6 months prior to registration; histopathological diagnosis of STS other than Ewing sarcoma, embryonal/alveolar rhabdomyosarcoma, well-differentiated liposarcoma and myxoid liposarcoma; prior doxorubicin-based chemotherapy for STS, and Eastern Cooperative Oncology Group performance status 0 to 2. The primary endpoint is progression-free survival, and the secondary endpoints include overall survival, disease-control rate, response rate, and adverse events. The total planned sample size to correctly select the most promising regimen with a probability of > 80% is 120. Thirty-seven institutions in Japan will participate at the start of this trial. Discussion This is the first randomized trial to evaluate trabectedin, eribulin, and pazopanib as second-line therapies for advanced STS. We endeavor to perform a subsequent phase III trial comparing the best regimen selected by this study (JCOG1802) with GD. Trial registration This study was registered with the Japan Registry of Clinical Trials ( jRCTs031190152 ) on December 5, 2019.

Background Soft-tissue sarcomas (STS) are rare malignant tumors those are resistant to chemotherapy. We have previously reported the 3-year follow-up result on the efficacy of perioperative chemotherapy with doxorubicin (DXR) and ifosfamide (IFM) for high-risk STS of the extremities (JCOG0304). In the present study, we analyzed the 10-year follow-up results of JCOG0304. Methods Patients with operable, high-risk STS (T2bN0M0, AJCC 6th edition) of the extremities were treated with 3 courses of preoperative and 2 courses of postoperative chemotherapy, which consisted of 60 mg/m 2 of DXR plus 10 g/m 2 of IFM over a 3-week interval. The primary study endpoint was progression-free survival (PFS) estimated by Kaplan-Meier methods. Prognostic factors were evaluated by univariable and multivariable Cox proportional hazards model. Results A total of 72 patients were enrolled between March 2004 and September 2008, with 70 of these patients being eligible. The median follow-up period was 10.0 years for all eligible patients. Local recurrence and distant metastasis were observed in 5 and 19 patients, respectively. The 10-year PFS was 65.7% (95% CI: 53.4–75.5%) with no PFS events being detected during the last 5 years of follow-up. The 10-year overall survival was 78.1% (95% CI: 66.3–86.2%). Secondary malignancy was detected in 6 patients. The subgroup analysis demonstrated that there was significant difference in survival with regard to primary tumor size. Conclusions Only a few long-term results of clinical trials for perioperative chemotherapy treatment of STS have been reported. Our results demonstrate that the 10-year outcome of JCOG0304 for patients with operable, high-risk STS of the extremities was stable and remained favorable during the last 5 years of follow-up. Trial registration This trial was registered at the UMIN Clinical Trials Registry as C000000096 on August 30, 2005.

BackgroundThis randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS).MethodsPatients with localised high-risk STS in the extremities or trunk were randomised to receive AI or GD. The treatments were repeated for three preoperative and two postoperative courses. The primary endpoint was OS.ResultsAmong 143 enrolled patients who received AI (70 patients) compared to GD (73 patients), the estimated 3-year OS was 91.4% for AI and 79.2% for GD (hazard ratio 2.55, 95% confidence interval: 0.80–8.14, P = 0.78), exceeding the prespecified non-inferiority margin in the second interim analysis. The estimated 3-year progression-free survival was 79.1% for AI and 59.1% for GD. The most common Grade 3–4 adverse events in the preoperative period were neutropenia (88.4%), anaemia (49.3%), and febrile neutropenia (36.2%) for AI and neutropenia (79.5%) and febrile neutropenia (17.8%) for GD.ConclusionsAlthough GD had relatively mild toxicity, the regimen—as administered in this study—should not be considered a standard treatment of perioperative chemotherapy for high-risk STS in the extremities and trunk.Clinical trial registrationjRCTs031180003.

Management of the ischial fragment in acetabular fractures is a considerable problem. In this report, we presented how to drill or screw around the posterior column and ischium from the anterior approach using a novel ‘sleeve guide technique’ and the difficulty of plating. A sleeve, drill, depth gauge and driver from DepuySynthes were prepared. The portal was about 2–3 cm inside the anterior superior iliac spine opposite to the side of the fracture. The sleeve was inserted to the screw point around quadrilateral area through the retroperitoneal space. Drilling, measuring screw length by a depth gauge and the screwing were performed through the sleeve. Case 1 used a one-third plate and case 2 used a reconstruction plate. With this technique, the approach angles to the posterior column and ischium were inclined, and plating and screw insertion could be performed with a low risk of organ injury.

Background Soft tissue sarcomas (STS) are rare malignant tumors. The efficacy of preoperative chemotherapy for STS is evaluated using various tumor size-based radiological response criteria. However, it is still unclear which set of criteria would show the best association with pathological response and survival of the patients with STS. Methods We compared radiological responses to preoperative chemotherapy for operable STS by the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST, World Health Organization criteria, Japanese Orthopaedic Association criteria, and modified Choi criteria and analyzed the association with pathological response and survival using the data from the Japan Clinical Oncology Group (JCOG) study JCOG0304, a phase II clinical trial evaluating the efficacy of perioperative chemotherapy for STS in the extremities. Results Seventy eligible patients in JCOG0304 were analyzed. The results demonstrated that none of the size-based radiological response criteria showed significant association with pathological response to preoperative chemotherapy for STS. The difference between overall survival of the patients assessed as partial response and stable disease/progressive disease by RECIST was not significant (hazard ratio 1.37, p  = 0.63), and calculated C-index was 0.50. All other response criteria also could not exhibit significant association between radiological responses and survival. Conclusion In the present study, none of the radiological response criteria analyzed demonstrated association of response to preoperative chemotherapy with pathological response or survival of the patients with operable STS. Further prospective investigation is required to develop criteria to evaluate not only tumor shrinkage but biological effects of preoperative chemotherapy for the patients with localized STS. Trial registration UMIN Clinical Trials Registry C000000096. Registered 30 August, 2005 (retrospectively registered).